| Name | Title | Contact Details |
|---|
Universal Sompo is a Joint venture of Indian Bank, Indian Overseas Bank, Karnataka Bank, Dabur Investments, and Sompo Japan Insurance Inc. The companys paid-up capital is Rs 368 Cr; Shareholders Net worth is over Rs. 1269 Cr ; Gross Written Premium Rs. 4169 Cr ; Assets Under Management (AUM) Rs. 4386 Cr; Solvency at 1.73 times. The company is headquartered in Mumbai and has 151 offices countrywide with representation through its digitally enabled employees. It has a strong distribution network of Agents, Point of salespersons, Bank Branches, Automobile Dealers, Brokers, Common Service Centres, and Digital Platforms. The company offers 234 IRDAI-approved products and 1494 Add-on covers, ranging from Motor, Accident & Health, Home for Individuals, Shopkeepers Package, Crop and other non-life packages for SMEs, Fire, Marine, Engineering, Employees Benefit, Project Insurance, Liability, and other special products for Corporates. Microinsurance covers the Rural segment. The company maintains its Claims settlement ratio at 98.87% and has robust technology architecture to serve its customers nationwide.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Cloud Giants provides consulting services to midsize B2B organizations in the Salesforce ecosystem looking to accelerate revenue operations. Through a unique blend of Salesforce expertise, technical proficiency and business acumen, we drive results and influence meaningful KPIs aligned to your business objectives. Cloud Giants specializes in: Increasing the velocity of revenue operations Reducing friction in the selling process Providing process transparency to all teams involved in the revenue lifecycle Simplifying and automating business processes Enhancing and streamlining the buyer experience Minimizing technical debt and delivering quicker time to value Our expertise includes Revenue Cloud/CPQ, Sales Cloud, and Experience Cloud solutions.
Scale your team with high-quality, vetted professionals. 🚀 MSH is a global technology and talent solutions provider that empowers people and the places they work to thrive. The companys leading-edge services and support provide organizations with the business intelligence and high-quality, vetted candidates they need to succeed at a speed and scale others cannot in 35+ markets across three continents. By engaging MSHs human-centered and collaborative platform, hiring leaders and talent professionals are empowered to find the highest quality candidates, while putting the candidate experience front and center. Founded in 2011 and headquartered in Fort Lauderdale, Fla., MSH is certified as a Minority Business Enterprise by the National Minority Supplier Development Council.